FoundationOne Liquid CDx
FDA-approved liquid biopsy CGP assay analyzing ctDNA from blood to detect genomic alterations in solid tumors and guide use of targeted therapies.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
FoundationOne Liquid CDx is an FDA-approved, cfDNA-based next-generation sequencing assay that profiles over 300 cancer-related genes from a simple blood draw. By detecting key genomic alterations in solid tumors, it supports therapy selection as a companion diagnostic and can inform eligibility for multiple targeted treatments.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Breast Cancer | PIK3CA | alterations (including mutations) | ITOVEBI + IBRANCE + FASLODEX |
| C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y | PIQRAY | ||
| Metastatic Castrate Resistant Prostate Cancer (mCRPC) | BRCA1 and BRCA2 | alterations (including mutations) | AKEEGA, LYNPARZA + ZYTIGA, RUBRACA |
| BRCA1, BRCA2 and ATM | alterations (including mutations) | LYNPARZA | |
| Metastatic Colorectal Cancer (mCRC) | BRAF | V600E | BRAFTOVI + ERBITUX |
| Non-Small Cell Lung Cancer (NSCLC) | ALK | gene rearrangements | ALECENSA |
| BRAF | V600E | BRAFTOVI + MEKTOVI | |
| EGFR (HER1) | Exon 19 deletion or exon 21 L858R substitution mutation | IRESSA, LAZCLUZE + RYBREVANT, TAGRISSO, TARCEVA | |
| Exon 20 insertions | EXKIVITY | ||
| MET | single nucleotide variants and indels that lead to MET exon 14 skipping | TABRECTA, TEPMETKO | |
| ROS1 | fusions | ROZLYTREK | |
| Solid Tumors | NTRK1, NTRK2 and NTRK3 | fusions | ROZLYTREK |
Performing lab
Boston Lab (22D2027531)
At Foundation Medicine, our mission is to transform lives in cancer and beyond. We strive to provide multi-modal precision diagnostic solutions to transform cancer care throughout a patient’s experience, from pre-diagnosis to ongoing management and monitoring. Leveraging our vast knowledge of precision medicine, we partner with biopharmaceutical companies to accelerate the development of new personalized therapies in cancer and in a range of other diseases. For more information, visit us at www.FoundationMedicine.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
Order this test
If your organization is connected to Casandra, you can place an electronic order forFoundationOne Liquid CDx directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.